The US FDA has accepted its new drug tucatinib/Tukysa plus trastuzumab for priority approval eligibility in the treatment of patients with HER2-positive CRC who have undergone at least one past therapy for disease that cannot be resected or developed metastasis. This evidence concerns the gene ERBB2 and colorectal carcinoma.